Abstract: A method implemented by computer means for training a decision system for segmenting medical images from a training set of annotated medical images, the segments belonging to at least one class, each annotation of the medical images including quantitative information about a number of pixels of the image that belongs to each of the classes, the method using weakly-supervised algorithm based on a percentage of the pixels of the image belonging to a concerned class.

Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.

Abstract: Disclosed is a method for fabricating an optical component that is configured so as to generate on an illumination target in the near-field an illumination that has a determined pattern according to which each point (i) of the illumination target receives a quantity of light (alpha i) via an illumination generated by an illumination light source that is incident on the optical component, which is placed between the illuminating light source and the illumination target.

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.

Abstract: A spectroscopy device including: an electron source arranged to emit a flux of electrons towards a sample, a pulsed photon source emitting photon pulses towards the sample, at least one spectrometer for receiving a flux of electrons originating from the sample, at least one electron detector; and at least one deflector, between the electron source and the at least one electron detector, synchronized with the pulsed photon source to allow or prevent the passage of electrons emitted by the electron source, towards the electron detector.

Abstract: The present invention relates to a method for screening compounds for bactericidal activity using thermostable luciferase and based on a real-time bioluminescence measurement. The present invention further relates to a method for determining the sensitivity of a bacterial sample originating from a subject suffering from a bacterial infection to a group of known antibiotics and to a method for assessing the minimum inhibitory concentration (MIC) of a bactericidal compound.

Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.

Abstract: A device for supplying an ultrasonic transducer including a power interface configured to provide an analog power signal, called supply signal, to the ultrasonic transducer, and further including a delta-sigma modulator configured to produce a delta-sigma modulator of a sinusoidal signal, called drive signal, and provide a digital signal, called control signal, to control said power interface. Also an ultrasonic device powered by such a supply device, an ultrasonic head including such ultrasonic devices and an ultrasonic system including such an ultrasonic head.

Abstract: The present invention relates to compounds simultaneously having thermally activated delayed fluorescence (TADF), circularly polarised luminescence (CPL) and aggregation-induced emission enhancement (AIEE) properties. The invention also relates to the use of such compounds as a photocatalyst or as a dopant, in particular in the emitting layers of light-emitting diodes (OLEDs), as well as light-emitting devices or light-emitting diodes (OLEDs) comprising such compounds.

Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

Abstract: The present invention relates to phage T5 capsids that are devoid of genomic DNA from the phage and exposing, on their surface, at least one fusion protein of interest.

Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.

Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.

Abstract: The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: A bioconjugate comprising at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure.